Abstract 11785: Impact of Ranolazine on Clinical Outcomes and Health Care Resource Utilization in Patients With Angina Pectoris
Background. Ranolazine is a novel antianginal medication approved for treatment of chronic angina. There is only limited data concerning the efficacy of ranolazine in reducing health care resource utilization in patients (pts) with chronic angina. The primary objective of this analysis will be to evaluate the efficacy of ranolazine in pts with chronic angina pectoris. In addition, the impact of ranolazine on health-care resource utilization will be assessed.
Methods. Consecutive pts with angina pectoris treated with ranolazine at 2 cardiology practices were included in this analysis. The Canadian Cardiovascular Society (CCS) angina class and frequency and type of health-care resource consumption were determined during the 12 months prior to and during the 12 months after initiation of ranolazine. The dosage regimen, duration of therapy, and adverse effects of ranolazine were also evaluated.
Results. 150 pts (64% men) with a mean age of 66 ± 12 years were included in this analysis. 99% and 95% had previously undergone PCI and CABG, respectively. Long-acting nitrates, beta-blockers, and calcium antagonists were being used in 83%, 97%, and 75% of pts, respectively. The initial ranolazine dose was 860 ± 278 mg/d with a final dose of 1616 ± 526 mg/d with 1.06 ± 0.8 dose titrations. 37 adverse effects occurred in 28 (19%) pts with 4 adverse effects requiring dose reduction and 7 requiring drug discontinuation. Percentage of patients in each CCS angina class at baseline was 8% in class 2, 58% in class 3, and 34% in class 4. At the end of ranolazine therapy, those percentages were 19% in class 2, 52% in class 3, and 29% in class 4. During the pre-ranolazine period, the number of visits per patient per year for clinic visits, ER visits and hospital visits were 2.85, 0.39, and 0.91, respectively. During the post-ranolazine period, the number of visits per patient per year for clinic visits, ER visits, and hospital visits were reduced to 2.79, 0.28, and 0.64, respectively.
Conclusion. Ranolazine improved the CCS angina class and reduced health-care resource consumption over a 12 month follow-up period in a difficult to treat group of patients with severe angina pectoris.
- © 2012 by American Heart Association, Inc.